DHL enhances its healthcare logistics by acquiring CRYOPDP.

DHL Group has acquired CRYOPDP, a prominent specialty courier specializing in clinical trials, biopharma, and cell and gene therapies, further strengthening its supply chain services in the life sciences sector. This acquisition is vital for DHL's strategy to enhance its pharma logistics capabilities and expand its offerings, contributing over €5 billion in global revenue in 2024. The partnership will enable integrated end-to-end solutions, targeting growth in key markets like Asia Pacific and EMEA, while aligning with DHL's Strategy 2030 goals for temperature-controlled networks and improved service levels.